All Stories

  1. Anticancer Properties of Antipsychotic Drugs

    Article • January 2024, Springer Science + Business Media

    Prof. Milica M. Borovcanin

  2. Stratification in Immunopsychiatry

    Article • January 2024, Springer Science + Business Media

    Prof. Milica M. Borovcanin

  3. Effects of Antipsychotics on Bone Mineral Density in Schizophrenia

    Article • Experimental and Applied Biomedical Research (EABR), December 2023, De Gruyter

    Prof. Milica M. Borovcanin

  4. Diabetes mellitus type 2 as an underlying, comorbid or consequent state of mental disorders

    Article • World Journal of Diabetes, May 2023, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Prof. Milica M. Borovcanin

  5. Neuroimmune, clinical and treatment challenges in multiple sclerosis-related psychoses

    Article • World Journal of Psychiatry, April 2023, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Prof. Milica M. Borovcanin

  6. Targeting Underlying Inflammation in Carcinoma Is Essential for the Resolution of Depressiveness

    Article • Cells, February 2023, MDPI AG

    Prof. Milica M. Borovcanin

  7. Prescription of selective serotonin reuptake inhibitors in COVID-19 infection needs caution

    Article • Frontiers in Psychiatry, October 2022, Frontiers

    Prof. Milica M. Borovcanin

  8. Galectin-3 mediated risk of inflammation in stable schizophrenia, with only possible secondary consequences for cognition

    Article • World Journal of Psychiatry, September 2022, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Prof. Milica M. Borovcanin

  9. Galectin-3 Involvement in Cognitive Processes for New Therapeutic Considerations

    Article • Frontiers in Cellular Neuroscience, July 2022, Frontiers

    Prof. Milica M. Borovcanin

  10. The Influence of Serum Uric Acid on the Brain and Cognitive Dysfunction

    Article • Frontiers in Psychiatry, April 2022, Frontiers

    Prof. Milica M. Borovcanin

  11. Uric Acid Potential Role in Systemic Inflammation and Negative Symptoms After Acute Antipsychotic Treatment in Schizophrenia

    Article • Frontiers in Psychiatry, February 2022, Frontiers

    Prof. Milica M. Borovcanin

  12. Autoimmunity and psychosis

    Article • January 2022, Elsevier

    Prof. Milica M. Borovcanin

  13. P.0010 Psychiatry trainees’ attitudes, knowledge and training in addiction psychiatry - a European survey

    Article • European Neuropsychopharmacology, December 2021, Elsevier

    Prof. Milica M. Borovcanin

  14. Breast cancer in schizophrenia could be interleukin-33-mediated

    Article • World Journal of Psychiatry, November 2021, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Prof. Milica M. Borovcanin

  15. Galectin-3 possible involvement in antipsychotic-induced metabolic changes of schizophrenia: A minireview

    Article • World Journal of Diabetes, October 2021, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Prof. Milica M. Borovcanin

  16. Contrasting Roles of the Galectin-3 in the Schizophrenia Onset, Clinical Presentation, and Somatic Comorbidity

    Article • Current Topics in Medicinal Chemistry, June 2021, Bentham Science Publishers

    Prof. Milica M. Borovcanin

  17. Psychiatry Trainees' Attitudes, Knowledge, and Training in Addiction Psychiatry—A European Survey

    Article • Frontiers in Psychiatry, January 2021, Frontiers

    Prof. Milica M. Borovcanin

  18. Chlorpromazine as a Potential Antipsychotic Choice in COVID-19 Treatment

    Article • Frontiers in Psychiatry, December 2020, Frontiers

    Prof. Milica M. Borovcanin

  19. Type 17 Immune Response Facilitates Progression of Inflammation and Correlates with Cognition in Stable Schizophrenia

    Article • Diagnostics, November 2020, MDPI AG

    Prof. Milica M. Borovcanin

  20. Peripheral Markers of Immune Response in Major Psychiatric Disorders: Where Are We Now and Where Do We Want to Be?

    Article • January 2019, Frontiers

    Prof. Milica M. Borovcanin

  21. The use of complementary serological and molecular testing for blood-borne pathogens and evaluation of socio-demographic characteristics of intravenous drug users on substitution therapy from Sumadia district of Serbia

    Article • Vojnosanitetski pregled, January 2019, National Library of Serbia

    Prof. Milica M. Borovcanin

  22. Oxidative stress and neuroinflammation should be both considered in the occurrence of fatigue and depression in multiple sclerosis

    Article • Acta Neurologica Belgica, September 2018, Springer Science + Business Media

    Prof. Milica M. Borovcanin

  23. IL-33/ST2 Pathway and Galectin-3 as a New Analytes in Pathogenesis and Cardiometabolic Risk Evaluation in Psychosis

    Article • Frontiers in Psychiatry, June 2018, Frontiers

    Prof. Milica M. Borovcanin

  24. Interplay of Brain-Derived Neurotrophic Factor and Cytokines in Schizophrenia

    Article • Serbian Journal of Experimental and Clinical Research, February 2018, Centre for Evaluation in Education and Science (CEON/CEES)

    Prof. Milica M. Borovcanin

  25. POSITIVE IMPACT OF PRESCRIBED PHYSICAL ACTIVITY ON SYMPTOMS OF SCHIZOPHRENIA: RANDOMIZED CLINICAL TRIAL

    Article • Psychiatria Danubina, November 2017, Medical Publishing, d.o.o.

    Prof. Milica M. Borovcanin

  26. Interleukin-6 in Schizophrenia—Is There a Therapeutic Relevance?

    Article • Frontiers in Psychiatry, November 2017, Frontiers

    Prof. Milica M. Borovcanin

  27. Cross-national Trainee Collaboration-The EFPT Research Experience in Psychiatry

    Article • European Psychiatry, April 2017, Cambridge University Press

    Prof. Milica M. Borovcanin

  28. Elevated sera levels of galectin-3 in stable schizophrenia

    Article • European Psychiatry, April 2017, Cambridge University Press

    Prof. Milica M. Borovcanin

  29. The EFPT-PSUD survey

    Article • European Psychiatry, April 2017, Cambridge University Press

    Prof. Milica M. Borovcanin

  30. Quality of Life in Primary Insomnia: Three-week Treatment With Zolpidem Vs. Lorazepam

    Article • Serbian Journal of Experimental and Clinical Research, January 2017, De Gruyter

    Prof. Milica M. Borovcanin

  31. In vivo methodology in behavioural pharmacology - where are we now?

    Article • Vojnosanitetski pregled, January 2017, National Library of Serbia

    Professor Jasna Jancic, Prof. Milica M. Borovcanin

  32. Possible Role of TGF – B Pathways in Schizophrenia / Moguća Uloga TTGF - B Signalnih Puteva U Shizofreniji

    Article • Serbian Journal of Experimental and Clinical Research, January 2016, De Gruyter

    Prof. Milica M. Borovcanin

  33. Cannabis as a Possible Treatment for Spasticity in Multiple Sclerosis / Kanabis Kao Moguci Tretman U Lecenju Spasticnosti Kod Multiple Skleroze

    Article • Serbian Journal of Experimental and Clinical Research, January 2016, De Gruyter

    Prof. Milica M. Borovcanin

  34. Depression correlates with sexual dysfunction and fatigue in multiple sclerosis patients

    Article • Journal of the Neurological Sciences, October 2015, Elsevier

    Prof. Milica M. Borovcanin

  35. Increase systemic levels of IL-23 as a possible constitutive marker in schizophrenia

    Article • Psychoneuroendocrinology, June 2015, Elsevier

    Prof. Milica M. Borovcanin

  36. The effect of antipsychotic drugs on nonspecific inflammation markers in the first episode of schizophrenia

    Article • Vojnosanitetski pregled, January 2015, National Library of Serbia

    Prof. Milica M. Borovcanin

  37. P.8.b.006 Side effects of zolpidem and temazepam in treating primary insomnia

    Article • European Neuropsychopharmacology, October 2014, Elsevier

    Prof. Milica M. Borovcanin

  38. Antipsychotics can modulate the cytokine profile in schizophrenia: Attenuation of the type-2 inflammatory response

    Article • Schizophrenia Research, June 2013, Elsevier

    Prof. Milica M. Borovcanin

  39. 2030 – Can TGF- β be a valuable marker for psychosis?

    Article • European Psychiatry, January 2013, Cambridge University Press

    Prof. Milica M. Borovcanin

  40. Elevated serum level of type-2 cytokine and low IL-17 in first episode psychosis and schizophrenia in relapse

    Article • Journal of Psychiatric Research, November 2012, Elsevier

    Prof. Milica M. Borovcanin

  41. Pharmacotherapeutical possibilities in mental disorders: Current status in Serbia

    Article • Srpski arhiv za celokupno lekarstvo, January 2011, National Library of Serbia

    Prof. Milica M. Borovcanin

  42. P.5.c.001 Memantine improves poststroke cognitive impairment supported with mirtazapine

    Article • European Neuropsychopharmacology, August 2010, Elsevier

    Prof. Milica M. Borovcanin

  43. PO18-WE-62 Seizures as predictive parameter in outcome of delirium tremens

    Article • Journal of the Neurological Sciences, October 2009, Elsevier

    Prof. Milica M. Borovcanin

  44. P.l.c.056 The most frequent used drugs at psychiatric clinical centre Kragujevac in 2007

    Article • European Neuropsychopharmacology, September 2009, Elsevier

    Prof. Milica M. Borovcanin